

# Regulation of *Otx2* expression and its functions in mouse forebrain and midbrain

Daisuke Kurokawa<sup>1</sup>, Hiroshi Kiyonari<sup>2</sup>, Rika Nakayama<sup>2</sup>, Chiharu Kimura-Yoshida<sup>1</sup>, Isao Matsuo<sup>1</sup> and Shinichi Aizawa<sup>1,2,\*</sup>

<sup>1</sup>Laboratory for Vertebrate Body Plan, Center for Developmental Biology (CDB), RIKEN Kobe, 2-2-3 Minatojima-minamimachi, Chuo-ku, Kobe 650-0046, Japan

<sup>2</sup>Laboratory for Animal Resources and Genetic Engineering, Center for Developmental Biology (CDB), RIKEN Kobe, 2-2-3 Minatojima-minamimachi, Chuo-ku, Kobe 650-0046, Japan

\*Author for correspondence (e-mail saizawa@cdb.riken.jp)

Accepted 8 April 2004

Development 131, 3319-3331  
Published by The Company of Biologists 2004  
doi:10.1242/dev.01220

## Summary

*Otx2* expression in the forebrain and midbrain was found to be regulated by two distinct enhancers (FM and FM2) located at 75 kb 5' upstream and 115 kb 3' downstream. The activities of these two enhancers were absent in anterior neuroectoderm earlier than E8.0; however, at E9.5 their regions of activity spanned the entire mesencephalon and diencephalon with their caudal limits at the boundary with the metencephalon or isthmus. In telencephalon, activities were found only in the dorsomedial aspect. Potential binding sites of OTX and TCF were essential to FM activity, and TCF sites were also essential to FM2 activity. The FM2 enhancer appears to be unique to rodent; however, the FM enhancer region is deeply conserved in gnathostomes. Studies of mutants lacking FM or FM2

enhancer demonstrated that these enhancers indeed regulate *Otx2* expression in forebrain and midbrain. Development of mesencephalic and diencephalic regions was differentially regulated in a dose-dependent manner by the cooperation between *Otx1* and *Otx2* under FM and FM2 enhancers: the more caudal the structure the higher the OTX dose requirement. At E10.5 *Otx1*<sup>-/-</sup>*Otx2*<sup>ΔFM/ΔFM</sup> mutants, in which *Otx2* expression under the FM2 enhancer remained, exhibited almost complete loss of the entire diencephalon and mesencephalon; the telencephalon did, however, develop.

Key words: *Otx2*, *Otx1*, Enhancer, Forebrain, Midbrain, Anterior neuroectoderm, WNT signaling, Mouse

## Introduction

The vertebrate brain is composed of telencephalon, diencephalon, mesencephalon and metencephalon. It is generally said that anterior neuroectoderm first develops into prosencephalic and mesencephalic vesicles; the mesencephalic vesicle comprises mesencephalon and metencephalon. Subsequently, the prosencephalon segregates into diencephalon and secondary prosencephalon, from which alar plates protrude to generate the telencephalon. However, it is still not certain how the rostral brain is organized ontogenically. Moreover, although it is widely accepted that the diencephalon is divided rostrocaudally into ventral thalamus, dorsal thalamus and pretectum, the rostrocaudal organization of the telencephalon is still a matter of dispute.

*Otx2*, *Six3* and *Rpx/Hesx1* are the genes expressed earliest in the anterior neuroectoderm induced by anterior visceral endoderm and anterior mesendoderm (Ang et al., 1994; Thomas and Beddington, 1996; Rhinn et al., 1998; Kimura et al., 2000). The initial morphological landmark in this anterior neural plate is the preotic sulcus, which corresponds to the future boundary between rhombomere 2 and 3; the sulcus becomes apparent around the one-somite stage. In the neural plate rostral to the sulcus, *Otx2* expression covers the entire future forebrain and midbrain, though its caudal limit is

initially not distinct. Within the *Otx2*-positive region, *Otx1* expression begins at around the two-somite stage (Simeone et al., 1992; Simeone et al., 1993; Suda et al., 1997). *Gbx2* expression in the region rostrally adjacent to the preotic sulcus, which corresponds to the future metencephalon, becomes apparent at around the three- to four-somite stage (Bouillet et al., 1995; Wassarman et al., 1997). *Otx2* and *Gbx2* expression initially overlap, but they become segregated by the six-somite stage, when the boundary between midbrain and hindbrain or isthmus is formed (Broccoli et al., 1999; Millet et al., 1999). Also at around the three- to four-somite stage, *Emx2* and *Pax6* expression begins in laterocaudal forebrain primordium (Suda et al., 2001; Inoue et al., 2000). At this stage, their caudal limits nearly coincide, but later *Emx2* expression is not found in the dorsal thalamus or pretectum, where *Pax6* is expressed. *Pax6* expression initially overlaps with *Pax2* expression caudally, but at around the six- to eight-somite stage its caudal margin coincides with the boundary between the diencephalon and mesencephalon (Araki and Nakamura, 1999; Schwarz et al., 1999; Matsunaga et al., 2000). Initially at the three-somite stage, *Pax2* expression covers the future entire midbrain (Rowitch and McMahon, 1995; Suda et al., 2001); however, as development proceeds it retracts caudally and is eventually found in caudal mesencephalon and metencephalon. *Six3* and

*Irx3* expressions also initially overlap, but by the six-somite stage they become segregated in avian. The anterior margin of the *Irx3* expression is delineated by zona limitans interthalamica (ZLTH) (Oliver et al., 1995; Bosse et al., 1997; Kobayashi et al., 2002). It has been suggested that the ZLTH divides the anterior neuroectoderm into rostral and caudal halves that differentially respond to FGF8 and SHH signaling (Crossley et al., 1996; Shimamura and Rubenstein, 1997; Martinez et al., 1999; Kobayashi et al., 2002). The isthmus and anterior neural ridge act as local organizers in midbrain and forebrain development, respectively. *Fgf8* expression is faint and broad at the three-somite stage, but it focuses at isthmus by the six-somite stage (Crossley and Martin, 1995; Suda et al., 1997). *Fgf8* expression also occurs in the anterior neural ridge at around the four-somite stage (Crossley and Martin, 1995; Shimamura and Rubenstein, 1997; Tian et al., 2002). Thus, the initial regionalization of the brain occurs at around the three- to six-somite stage.

The results of analyses of *Otx1*<sup>+/-</sup>*Otx2*<sup>+/-</sup> mutants suggested that *Otx2* and *Otx1* cooperate in the regionalization of the rostral brain (Acampora et al., 1997; Suda et al., 1996; Suda et al., 1997; Suda et al., 2001). Owing to the occurrence of earlier visceral defects in *Otx2*<sup>-/-</sup> mutants, however, this cooperation could not be examined in the *Otx2* homozygous mutant state. Furthermore, *Otx1*<sup>+/-</sup>*Otx2*<sup>+/-</sup> mutants are postnatally lethal, and *Otx1*<sup>-/-</sup> *Otx2*<sup>+/-</sup> phenotype could also not be examined. *Otx1*<sup>-/-</sup> mutants do not exhibit marked defects in forebrain or midbrain development (Suda et al., 1996). These situations obscured the onset and the extent of cooperation between *Otx1* and *Otx2* in rostral brain development.

Kurokawa et al. (Kurokawa et al., 2004) analyzed the enhancers of *Otx2* expression in anterior neuroectoderm at -95 to -80 kb. The activity of the AN enhancer ceased by E8.5 in anterior neuroectoderm. In the present study, we analyzed enhancers of *Otx2* expression in forebrain and midbrain; two distinct enhancers were identified at 75 kb 5' upstream and 115 kb 3' downstream. Their activities were absent in the entire forebrain and midbrain at E8.0 (two- to four-somite stage), but were found at E8.5 (6 to 8 somite stage). Thus, the transition of the activities from the AN enhancer to FM enhancer occurs at a stage crucial to rostral brain regionalization.

Studies of mutants lacking each of these enhancers demonstrated that they, in fact, regulate *Otx2* expression in vivo. Moreover, analysis of these mutants revealed that *Otx2* expression under FM and FM2 enhancers cooperates with *Otx1* in the development of the mesencephalon and diencephalon. The affected regions developed at E8.0 and were subsequently lost later than E8.5. The results of this investigation also suggested several upstream factors that are involved in the regulation of *Otx2* expression in forebrain and midbrain. Finally, the phylogenetic significance of enhancer organization was discussed on the basis of available genomic information.

## Materials and methods

See the accompanying paper (Kurokawa et al., 2004) for materials and methods not described here.

### Genomic clones of the *Otx2* locus of mouse and other animals

A mouse *Otx2* genomic BAC clone 391F17 here referred to as BAC #2 was isolated from a C57BL/6 BAC library (Research Genetics).

This was subdivided into fragments of about 10 to 15 kb in length by Sau3AI partial digestion and subcloned into *Bam*HI site of pBluescript SK (-). These clones were aligned as shown in Fig. 4A by walking. A 3 kb human genomic DNA in Fig. 5B, part c was amplified by PCR with 5'-ACTAGTTCTCAAAGTGTCCACTAA-GCCGCT-3' and 5'-CCATGCACCTGGGAAGCCCTAAAAAGATCA-3' as primers from RPC11-1085N6 (BACPAC resources) human *OTX2* BAC clone. A 0.6 kb zebrafish genomic DNA containing domain  $\beta$  in Fig. 8A, part b was amplified with 5'-GCTGGAATTGCTCTGGTCTTTTC-3' and 5'-CCAACTCTAAATCTAACATCACG-3' as primers from zebrafish genomic DNAs.

### Generation of BAC #2 transgenic mice

In order to generate the BAC #2 reporter transgene, a *lacZ* gene with the SV40 poly (A) signal was inserted into the translation start site of the 4.3 kb *Otx2* genomic fragment spanning -1.8 kb to +2.5 kb (Fig. 4A). Subsequently, the reporter was obtained by the BAC modification method of Yang et al. (Yang et al., 1997). The integrity of the BAC transgene in the mice was determined by PCR; primers for the 5' end were 1F (5'-TAACATGCGGCATCAGAGC-3') and 1R (5'-GCCTGCAGGTGCTAGTACAG-3') and those for the 3' end were 2F (5'-AGTATTCTATAGTGTACCT-3') and 2R (5'-CGTTGGCCGATT-CATTAATG-3').

### Generation of enhancer mutant mice

A neomycin resistance gene with Pgl1 promoter and SV40 polyadenylation signal was flanked by loxP sequences. This cassette (Neo) was replaced with the *Apa*I/*Hind*III 1314 bp or *Bsm*I/*Bam*HI 995 bp region to delete the FM or FM2 enhancer, respectively. Homologous recombinant ES clones were isolated with TT2 ES cells, as described previously (Matsuo et al., 1995). These were identified by PCR with 5'-ATCGCCTTCTTGACGAGTCTTCTG-3' in the *neo* gene as the 5' side primer and the following 3' side primers: 5'-CATAAGACCATGAGTTAGTTCACAGC-3' and 5'-CTGAACA-CACAATACTCCTCAGCTGG-3' for the FM and FM2 targeting vectors, respectively. Recombinants were confirmed by Southern blot analyses as described (Matsuo et al., 1995). Two mutant mouse lines were generated from independent homologous recombinant ES clones for each enhancer mutation. The genotype of each mutant mouse or embryo was routinely determined by PCR using tail or yolk sac specimens. Sense primers employed to detect the wild-type allele were 5'-GAGTGGCTTCTGTCTTTCCATTCCAC-3' (FM) and 5'-TTGTCAACCTCCTTTTGAAGAGCC-3' (FM2); 5'-ATCGCCTTCTTGACGAGTCTTCTG-3' (Neo) served as the primer to detect the mutant allele. The antisense primers were 5'-GAGCATGCTGCATCTCTGAAATACAC-3' (FM) and 5'-AAGACTGTCTCATTGGTGTGTTGC-3' (FM2). The deletion of the *neo* insert by Cre-mediated loxP recombination was accomplished by mating *Otx2*<sup>+ΔAN</sup> mice with *Lefty-Cre* mice (Yamamoto et al., 2001).


### RNA in situ hybridization

The probes used in this study were: *Emx2* (Yoshida et al., 1997), *Otx2* (Matsuo et al., 1995), *Fgf8* (Crossley and Martin, 1995) and *Pax6* (Walther and Gruss, 1991).

## Results

### 5' forebrain/midbrain enhancer

In a study described by Kurokawa et al. (Kurokawa et al., 2004), the enhancer of *Otx2* expression was mapped in forebrain and midbrain to a fragment (#13) located in the -80 kb to -70 kb 5' upstream region (Fig. 1A). This region exhibited no activity up to E8.0 in the anterior neuroectoderm (Fig. 1B, parts a,b), while activity was detected in the anterior neural plate at E8.5 (Fig. 1B, part c). After the closure of the neural tube,  $\beta$ -gal expression was observed in the



**Fig. 1.** Enhancer of *Otx2* expression in forebrain and midbrain at 5' upstream. (A) The location of the #13 fragment that exhibited the enhancer activity in forebrain midbrain. EP/AN indicates the position of the EP and AN enhancer at -92.5 to -90 kb. (B)  $\beta$ -Gal expression driven by #13 (a-f,m,q) and by endogenous enhancers in *Otx2*<sup>+/lacZ</sup> knock-in embryos (g-j,l,p), at the stages indicated. Endogenous *Otx2* mRNA expression is presented in k,n,o. (a,k-m) frontal views; (b-j) lateral views (anterior is towards the left); (n-q) frontal sections at the telencephalic level. Arrows and arrowheads indicate expression by the 1.8 kb promoter and the position of the isthmus, respectively. Double arrowheads in c indicate the absence of the  $\beta$ -gal expression in the most anterior neural plate, which may correspond to future telencephalon. Scale bars: 100  $\mu$ m in a,b,g; 400  $\mu$ m in c-f,h-q.

mesencephalon, diencephalon and the dorsomedio-caudal region of the telencephalon corresponding to the archencephalon (Fig. 1B, parts d-f,m). The caudal limit of  $\beta$ -gal expression coincided with the isthmus at E9.5 (Fig. 1B, parts d-f);  $\beta$ -gal expression persisted in these regions at E10.5. We named the enhancer identified in this region the FM (forebrain and midbrain) enhancer.

With BAC #1, which covered -170 kb to -30 kb 5' upstream, and the #12 fragment located at -90 to -92.5 kb,  $\beta$ -gal expression was found in the entire anterior neuroectoderm at E7.75, as described by Kurokawa et al. (Kurokawa et al., 2004). At E9.5, however, with either BAC#1 or the #13 fragment,  $\beta$ -gal expression was not detected in telencephalon with the exception of the dorsomedial region. At E8.5,  $\beta$ -gal expression was also absent in the most anterior neuroectoderm, which may correspond to the future telencephalon (double arrowheads in Fig. 1B, part c). To examine how the FM enhancer activity represents the endogenous *Otx2* expression in telencephalon, we re-evaluated the *Otx2* expression. At E9.5 and E10.5, mRNA expression was absent in the dorsal telencephalon except for the most dorsomedial aspect, while it was apparent in the ventral telencephalon (Fig. 1B, parts k,n,o).  $\beta$ -gal expression was also not found in the dorsal telencephalon

of *Otx2*<sup>+/lacZ</sup> embryos (Fig. 1, parts i,j,l,p), but was present in ventral telencephalon (Fig. 1B, part p). Thus, the anterior part of the neuroectoderm corresponding the future dorsal telencephalon initially exhibits *Otx2* expression under the control of the AN enhancer, but not under the FM enhancer beyond E8.5 when telencephalon develops. The enhancer of *Otx2* expression in the ventral telencephalon remains to be identified; neither the #13 fragment nor the #12 fragment (analyzed by Kurokawa et al., 2004) nor the #29 fragment described below exhibited any activity in ventral telencephalon at E10.5 (Fig. 1B, part q, data not shown).

To define the FM enhancer in the #13 fragment at -70 kb to -80 kb 5' upstream, the 10 kb region was divided into *XhoI/ApaI* 2.0 kb (XA2kb), *ApaI/HindIII* 1.4 kb (AH1.4kb), *HindIII/XbaI* 2.0 kb (HXb2kb) and *XbaI/ClaI* 3.0 kb (XbC3kb) fragments (Fig. 2A). The *ApaI/HindIII* 1.4 kb fragment exhibited full FM activity in a transient transgenic assay at E10.5. This finding was confirmed by the generation of permanent transgenic lines (Fig. 2C, part a).  $\beta$ -gal expression in the forebrain and midbrain was detected at E8.5 with this fragment. The caudal limit of  $\beta$ -gal expression occurred at the boundary between the midbrain and the hindbrain.

The 1.4 kb fragment is divided by a GT repeat into 5' 364


bp and 3' 904 bp sequences (Fig. 2B). A search of the human genome revealed a region that was 95% identical to the 5' 364 bp sequence at 82 kb 5' upstream of the human *OTX2* gene (Kurokawa et al., 2004). A homologous region (86% identical) was also discovered 36 kb 5' upstream of the *Xenopus Otx2* locus. By contrast, no region homologous to the 3' 904 bp was identified. The highly conserved 364 bp (CR) fragment drove  $\beta$ -gal expression in forebrain, whereas the 884 bp (NCR) fragment did not (Fig. 2A). CR activity was, however, limited to the diencephalon; the fragment could not drive  $\beta$ -gal expression in the mesencephalon (Fig. 2C, part b). Thus,

sequences that direct  $\beta$ -gal expression in mesencephalon in cooperation with the 364 bp sequences must be present in the remaining region of the *Apal/HindIII* 1.4 kb fragment. Putative binding sites for *Otx* and *Tcf/Lef* gene products (Mao et al., 1994; Brannon et al., 1997) (Fig. 2B) occur in the 364 bp fragment, and these binding sites are conserved in both human and *Xenopus* counterparts. To test their activity, transverse mutations were introduced to these sites in the *Apal/HindIII* 1.4 kb fragment. The fragment containing the mutation at the OTX binding site exhibited only residual activity in midbrain (arrowhead in Fig. 2C, part c). Moreover, a mutation in the two TCF/LEF binding sites completely abolished all activity necessary to drive  $\beta$ -gal expression in forebrain and midbrain (Fig. 2C, part d). The 364 bp sequence also contains a putative binding site for PAX (Czerny and Busslinger, 1995), which is conserved in the human locus, and which exhibits one base substitution in the *Xenopus* locus. A transverse mutation in this site did not affect the transcriptional activity of the *Apal/HindIII* 1.4 kb fragment (Fig. 2C, part e).


**Targeted disruption of *Otx2* FM enhancer activity**

In order to confirm that *Otx2* expression in forebrain and midbrain is governed by the FM enhancer after E8.5, a mutant, *Otx2<sup>ΔFM/ΔFM</sup>*, in which the *Apal/HindIII* 1.4 kb region was replaced with a cassette encoding a neomycin-resistant gene, was generated (Fig. 3A). In the homozygous enhancer mutant, *Otx2* expression was present, but diminished, at E9.5 (data not shown). Forebrain and midbrain development in this mutant also appeared normal (3B, parts a-d), suggesting that another enhancer of *Otx2* expression in forebrain/midbrain most probably exists.

Subsequently, a mutant in which one *Otx2* allele displayed deletion of the FM enhancer and in which the other allele was null, *Otx2<sup>ΔFM/-</sup>*, was generated. The mutant exhibited defects in midbrain and forebrain development. This finding demonstrated that the FM enhancer indeed functions as an enhancer of *Otx2* expression in forebrain/midbrain in vivo. Histologically, the telencephalon appeared normal and the ventral



**Fig. 2.** Deletion analysis of FM enhancer. (A) Fine mapping of the FM enhancer. (B) Schematic organization of the AH 1.4 kb subfragment and sequence alignment of the CR region in mouse, human and *Xenopus*. (C)  $\beta$ -gal expression at E10.5 driven by the AH 1.4 kb fragment (a), by the CR domain of the fragment (b) and by the AH 1.4 kb fragment exhibiting a mutation in the OTX binding site (c), in both TCF-binding sites (d) and in the PAX-binding site (e). Expression in midbrain is lost in b; furthermore, only residual expression exists in midbrain (arrowhead). Arrows indicate  $\beta$ -gal expression in cephalic mesenchyme driven by the 1.8 kb promoter. Scale bars: 400  $\mu$ m.



**Fig. 3.** Targeted disruption of FM enhancer. (A) Wild-type *Otx2* allele, targeting vector and recombinant allele. The black box indicates the *ApaI-HindIII* 1.4 kb region (FM) to be replaced with a neomycin-resistant gene (Neo, open boxes) flanked by *loxP* sequences (black triangles). DT-A is the diphtheria toxin A fragment gene with MC1 promoter, which is used for the negative selection of homologous recombinants (Matsuo et al., 1995). Thick and thin lines indicate genomic and vector-derived sequences, respectively. Probe A is the Southern blotting probe employed for identification of homologous recombinant ES cells displayed in the right panel. (B) FM enhancer mutant phenotype. Wild-type (a,b), *Otx2*<sup>ΔFM/ΔFM</sup> (c,d) and *Otx2*<sup>ΔFM/-</sup> (e,f) embryos at E12.5 (a,c,e) and E15.5 (b,d,f). A double arrowhead in f indicates the expanded cerebellum primordium. The phenotypes were examined with both the *Otx2*<sup>ΔFM</sup> mutant in which the neo insert remained and the *Otx2*<sup>ΔFM</sup> mutant in which the insert was deleted by Cre recombination. No differences were found, and the following marker analyses were performed with the mutant that retained the *neo* insert. (C) Marker analysis of *Otx2*<sup>ΔFM/-</sup> phenotype. *Otx2* (a,b), *Pax6* (c,d), *Fgf8* (e,f) and *Emx2* (g,h) expression in E10.5 wild-type (a,c,e,g) and *Otx2*<sup>ΔFM/-</sup> (b,d,f,h) embryos. Scale bars: 400 μm.

thalamus developed in *Otx2*<sup>ΔFM/-</sup> mutants (Fig. 3B, parts e,f). However, the development of the region posterior to the zona limitans, especially the midbrain, was poor, and additionally, the isthmus was shifted rostrally. In molecular terms (Fig. 3C), the *Otx2*-positive, *Pax6*-negative midbrain was nearly absent. The *Emx2*-positive forebrain was normal, whereas the *Pax6*-positive, *Emx2*-negative forebrain was reduced. The *Fgf8*-positive isthmus stripe was concomitantly shifted rostrally, and moreover, was expanded. At E15.5, the cerebellar primordium was also expanded in the *Otx2*<sup>ΔFM/-</sup> mutants (Fig. 3B, part f). The loss of mesencephalon and diencephalon in the mutants appears to be the consequence of a transformation into anterior hindbrain (Suda et al., 1997; Suda et al., 2001; Acampora et al., 1997).

BAC #1 displayed no transcriptional activity in posterior mesencephalon at E9.5 (see Fig. 1B, part c in the preceding paper), while the #13 fragment did exhibit this activity. As a result, the presence of a silencer in the BAC #1 was initially hypothesized. However, we could establish only one BAC


#1/*lacZ* transgenic line. The fact that the mesencephalon was affected in *Otx2*<sup>ΔFM/-</sup> mutants demonstrates rather that the FM enhancer in the *ApaI/HindIII* 1.4 kb fragment is active in midbrain in vivo.

### Search for the second enhancer in the 3' side of the coding region

Enhancer mutants indicated the presence of another enhancer of *Otx2* expression in forebrain/midbrain. To investigate this, a search was conducted for the second enhancer in the 3' region of the *Otx2* gene. A BAC transgenic mouse, which harbored a genomic DNA sequence that spanned -50 kb to +120 kb 3' downstream, was generated (BAC #2; Fig. 4A). The 3' BAC#2/*lacZ* transgene was prepared by homologous recombination in *E. coli* (Yang et al., 1997) between BAC#2 and a *lacZ* construct in which the *lacZ* gene was placed in-frame at the translational start site and flanked by 1.8 kb 5' and 2.5 kb 3' sequences. Two 3' BAC#2/*lacZ* transgenic lines were produced, neither of which displayed activity in epiblast or

anterior neuroectoderm. At a later point, these lines exhibited activities in forebrain, midbrain, eyes and nose (Fig. 4B, part a).

The *Otx2* 3' genomic region was then divided into 14



**Fig. 4.** Search for enhancers of *Otx2* expression in ectoderm at 3' downstream. (A) The 3' BAC #2/*lacZ* transgene and the 14 fragments assayed for enhancer activity. (B)  $\beta$ -Gal expression driven by the 3' BAC #2/*lacZ* transgene (a), by #17 in nasal placode (b), by #20 in nasal cavity (c) and by #29 in forebrain and midbrain (d-i) at indicated stages. Open arrows,  $\beta$ -gal expression in eyes; double arrows,  $\beta$ -gal expression in nasal placode or cavity; arrowheads, the position of the isthmus. The activity of the 1.8 kb promoter in cephalic mesenchyme (indicated by an arrow in b) is suppressed by the 3' BAC #2 (a) and the #29 fragment (f,h); by contrast, promoter activity in anterior mesoderm is not (an arrow in d). Open arrowheads in d indicate weak  $\beta$ -gal expression in the future mid/hindbrain boundary region. With the exception of the nasal cavity, expression in c is ectopic. In lateral views (a-c,e-h), anterior is towards the left; (d,i), frontal views. Scale bars: 400  $\mu$ m.

fragments, and the enhancer activity of each fragment was assayed via generation of permanent transgenic lines, as indicated in the parentheses in Fig. 4A. No activity was detected in epiblast or anterior neuroectoderm with any of these fragments. The #17 and #20 fragments showed activity in nasal placode (Fig. 4B, parts b,c). However, the enhancer of expression in E9.5 forebrain and midbrain was mapped to the #29 fragment, which locates at +110 kb to +120 kb 3' downstream. This fragment displayed faint activity at E7.75 in the future mid/hindbrain boundary region (Fig. 4B, part d). Furthermore, activity was evident in future dorsal areas of the prospective mid/hindbrain boundary region at E8.5 (Fig. 4B, part e). At E9.5,  $\beta$ -gal expression directed by #29 covered the entire mesencephalon (Fig. 4B, parts f,g).  $\beta$ -gal expression in mesencephalon and diencephalon declined at E10.5 (Fig. 4B, parts h,i). However, intensive  $\beta$ -gal expression continued in the dorsocaudal telencephalon. With the exception of this aspect, the #29 fragment did not exhibit activity in telencephalon, as was true of the FM enhancer. The enhancer in the #29 fragment was designated as the FM2 enhancer.

After E9.5 the endogenous *Otx2* expression in the dorsal telencephalon is found in its medial aspect (Fig. 1B, parts k,l,n-p). At E10.5, the AN, FM and FM2 enhancers all had differential activities in this region, the significance of which remains for future studies (Fig. 1B, parts m,q; Fig. 4B, part i) (Kurokawa et al., 2004).


### 3' forebrain/midbrain enhancer

The #29 10 kb region was divided into *MluI/SalI* 2.5 kb (MS2.5kb), *SalI/SpeI* 2.5 kb (SS2.5kb), *SpeI/BamHI* 2.8 kb (SB2.8kb) and *BamHI/HindIII* 1.2 kb (BH1.2kb) fragments to characterize the FM2 enhancer (Fig. 5A). FM2 enhancer activity was inherited by the *SpeI/BamHI* 2.8 kb fragment (Fig. 5B, part a). The *BamHI/HindIII* fragment exhibited activity in the cortical area (Fig. 5B, part b); however, this activity was not observed with the BAC #2 or the #29 fragment. Moreover, no endogenous *Otx2* expression was detected in the cortex (Fig. 1Bi-l, n-p). Based on these, no further analysis was conducted on the *BamHI/HindIII* fragment.

In the *SpeI/BamHI* 2.8 kb fragment, the 5' 700 bp region is well conserved between mouse and human with sequence identity of 81%; however, no region homologous to the 3' 2.1 kb region (NCR) exists in the human or *Xenopus* genome. Sequence identity of the NCR region between mouse and rat is 83%. Unexpectedly, FM2 enhancer activity was present in this NCR region (Fig. 5A). Subsequently, the NCR was divided into *HincII* 1.3 kb and *BsmI/BamHI* 1 kb (BB1.0kb) fragments. The BB 1.0 kb subfragment retained enhancer activity of expression in forebrain and midbrain. Moreover, its sequence identity with the rat counterpart region was 83%. This fragment, however, exhibited intense ectopic activity in the trunk dorsal root ganglion (DRG). This finding was confirmed via generation of permanent transgenic lines (Fig. 5B, part d). Expression in DRG was faint with the SB 2.8 kb fragment (arrowhead in Fig. 5B, part a) and moderately increased with NCR.  $\beta$ -Gal expression was observed at E8.5 in midbrain with the BB 1.0 kb fragment to an extent similar to that of the #29 fragment (Fig. 4B, part e). Expression persisted until E10.5, after which it gradually decreased.

Further deletion of the *BsmI/HincII* 127 bp region at the 5' end of the BB 1.0 kb fragment drastically reduced enhancer

**Fig. 5.** Deletion analysis of FM2 enhancer. (A) Fine mapping of the FM2 enhancer. Blue boxes indicate the domains conserved between human and mouse characterized by sequence identity exceeding 80% over more than 100 bp. Sequences in the boxes denoted by P were used as primers to isolate the counterpart 3.0 kb region in human genome by PCR. Asterisk in HB 0.9 kb indicates residual expression shown in (Be). Percentages on each bar provide the sequence identity of each domain with human or rat. (B)  $\beta$ -Gal expression driven by the SB 2.8 kb fragment (a), by the BH 1.2 kb fragment (b), by the human 3.0 kb counterpart of the SB 2.8 kb region (c), by the BB 1.0 kb fragment (d), by the HB 0.9 kb fragment (e), by the BB 1.0 kb fragment with mutations in three TCF binding sites (f) and by the BP 200 bp fragment (g) at E10.5 (a-f) and at E11.5 (g). Arrowheads in a and e indicate faint ectopic expression in DRG and residual expression in dorsal midbrain, respectively. Arrows indicate  $\beta$ -gal expression in cephalic mesenchyme by the 1.8 kb promoter. Scale bars: 400  $\mu$ m. (C) Alignment of nucleotide sequences of BP 200 bp between mouse and rat.



activity (HB 0.9 kb; Fig. 5A and 5B, part e), although residual activity remained in midbrain. Thus, the 5' region is essential for FM2 activity. This region displays 91% sequence identity between mouse and rat and includes three TCF/LEF binding sites, all of which are conserved in the rat *Otx2* locus (Fig. 5C). Mutations in all three TCF/LEF binding sites nearly abolished the enhancer activity of the mouse BB 1.0 kb fragment (Fig. 5B, part f). However, the BP 200 bp fragment (Fig. 5A) containing *BsmI/HincII* 127 bp failed to capture FM2 activity, but directed disorganized expression (Fig. 5B, part g).


It has been shown that enhancer activity can be conserved in spite of the high divergence of the sequences overall if the core sequences for transcription are conserved (Flint et al., 2001; Müller et al., 2002). NCR demonstrating FM2 activity occurs between the domains conserved in the human genome (blue boxes in Fig. 5A). This region in the human genome (human 3.0 kb) was isolated by PCR employing conserved sequences (indicated by P in blue boxes of Fig. 5C) and was then tested for enhancer activity. No consensus sequences for TCF binding sites exist in the human 3.0 kb, nor was any FM activity detected with human 3.0 kb (Fig. 5B, part c).

**Targeted disruption of FM2 enhancer activity**

In order to confirm that *Otx2* expression in forebrain and midbrain is also governed by the FM2 enhancer later than E8.5, a mutant was generated in which the *BsmI/BamHI* 1.0 kb region was replaced with a cassette encoding a neomycin-resistant gene (Fig. 6A). The homozygous mutant, *Otx2<sup>ΔFM2/ΔFM2</sup>*, demonstrated normal forebrain and midbrain development (Fig. 6B, parts a,b). However, the mutant in which one *Otx2* allele displayed deletion of the FM2 enhancer and in which the other allele was null, *Otx2<sup>ΔFM2/-</sup>*, exhibited defects in midbrain and forebrain development (Fig. 6B, parts c,d) similar to those observed in *Otx2<sup>ΔFM/-</sup>* (Fig. 3B). Marker analyses indicated that the defects in the *Otx2<sup>ΔFM2/-</sup>* mutant were milder (Fig. 6C) than those in

the *Otx2<sup>ΔFM/-</sup>* (Fig. 3C). Reductions of the *Emx2*-negative, *Pax6*-positive region and *Pax6*-negative, *Otx2*-positive regions were minimal, and the anterior shift and expansion of the *Fgf8*-positive isthmus was less pronounced.

The *Otx2<sup>ΔFM/-</sup>* and *Otx2<sup>ΔFM2/-</sup>* phenotypes were similar to those observed in *Otx1<sup>+/-</sup>Otx2<sup>+/-</sup>* defects reported previously (Fig. 7A, part d) (Suda et al., 1997). A series of mutants were produced to assess the cooperation of *Otx1* with *Otx2*



**Fig. 6.** Targeted disruption of FM2 enhancer. (A) Diagrammatic representation of wild-type *Otx2* allele, targeting vector and recombinant allele. The black box indicates the *BsmI*-*BamHI* 1.0 kb region (FM2) to be replaced with a neomycin-resistant gene (Neo) (see Fig. 3A for others). (B) *Otx2*<sup>ΔFM2/ΔFM2</sup> (a,b) and *Otx2*<sup>ΔFM2/-</sup> (c,d) phenotype at E12.5 (a,c) and E15.5 (b,d). The phenotypes were examined with both the *Otx2*<sup>ΔFM2</sup> mutant in which the neo insert remained and the *Otx2*<sup>ΔFM2</sup> mutant in which the insert was deleted by Cre recombination. No differences were found, and the following, marker analyses were performed with the mutant that retained the *neo* insert. (C) Marker analysis of *Otx2*<sup>ΔFM2/-</sup> phenotype at E10.5; *Otx2* (a), *Pax6* (b), *Fgf8* (c) and *Emx2* (d) expression (see Fig. 3C for the expression in wild-type embryos). Scale bars: 400 μm.


expression under the FM and FM2 enhancers (Fig. 7A). These mutants indicated that the development of mesencephalic and diencephalic regions is dependent on OTX dose. In the most severe *Otx1*<sup>-/-</sup>*Otx2*<sup>ΔFM/ΔFM</sup> mutant, in which *Otx2* expression under the FM2 enhancer remains, the *Emx2*-negative, *Pax6*-positive domain and the *Emx2*-negative, *Otx2*-positive domain were residual at E10.5 (Fig. 7B). Thus, diencephalon and mesencephalon were almost entirely missing, but the *Emx2*-positive telencephalon developed normally (Fig. 7B, part d). This is consistent with a lack of FM activity in telencephalon. Moreover, the FM enhancer did not have the activity at E8.0, and *Otx2*<sup>-/-</sup>, *Emx2*<sup>-/-</sup> and *Pax2*-positive regions developed normally at the five-somite stage in *Otx1*<sup>-/-</sup>*Otx2*<sup>ΔFM/ΔFM</sup> mutants as expected (data not shown). Furthermore, in a series of double mutants in Fig. 7A, the lower the *Otx* dose and the more severe the phenotype, the more expanded the *Fgf8*-positive isthmus (Fig. 3C, Fig. 6C and data not shown). Interestingly, however, *Fgf8*-positive isthmus was lost in the most severe *Otx1*<sup>-/-</sup>*Otx2*<sup>ΔFM/ΔFM</sup> mutant (Fig. 7B, part c). This mutant also lacked the *Fgf8* expression in the anterior neural ridge.

### FM enhancer is deeply conserved in gnathostome

The expression pattern of the *Otx* family of genes in zebrafish is divergent from that in tetrapods (Li et al., 1994; Mori et al., 1994; Mercier et al., 1995). Among teleosts, genome information is available for pufferfish (*Fugu rubripes*) and zebrafish. The 22 domains conserved in tetrapod *Otx2* loci were

assigned to the loci of all *Otx* homologues in these species. The FM2 enhancer, which was not conserved in human or *Xenopus*, was also not conserved in the genomes of these fish. The pufferfish possesses one *Otx1* and two *Otx2* homologues; at the moment, these homologues are denoted as *FrOtx1*, *FrOtx2a* (Ensembl Gene ID is SINFRUG00000151879) and *FrOtx2b* (Ensembl Gene ID is SINFRUG00000136398) (Fig. 8A). Eight domains (β, ζ, η, θ, ι, κ, ξ and ρ) are conserved in both pufferfish and zebrafish *Otx* genes. Domains α and γ are conserved exclusively in zebrafish and domain o exclusively in pufferfish. In pufferfish, none of these domains is conserved in the *FrOtx1* locus; by contrast, one (θ) and two domains (γ, κ) are conserved in *Otx3* and *Otx1*, respectively, in zebrafish. Domain δ, which harbors the EP and AN enhancers in tetrapods, is not conserved in the pufferfish or the zebrafish genome. Among the eight domains conserved in mouse, human, *Xenopus*, pufferfish and zebrafish, β, θ and ρ demonstrated enhancer activity in the mouse, as described above. Domain β harbored the FM enhancer, whereas domain θ exhibited activity in regions of ventral diencephalon and dorsal mesencephalon. Domain ρ displayed activity in nasal placode. Regions homologous to domain β are present in *FrOtx2a*, *FrOtx2b* and zebrafish *Otx2* loci. These regions retained OTX and a single TCF/LEF binding site (Fig. 8B). Another TCF/LEF binding site was converted into a SOX-binding site in zebrafish and pufferfish via a one-base substitution (Mertin et al., 1999). The conservation of TCTAATTAATAAWGGATA (red box in Fig.





**Fig. 7.** Cooperation between *Otx1* and *Otx2* under FM and FM2 enhancers. (A) Histological features of a series of double mutants at E12.5; the genotype of each mutant is indicated at the left. Among mutants not shown, defects were either absent or subtle in *Otx2*<sup>ΔFM2/ΔFM2</sup>, *Otx1*<sup>+/-</sup> *Otx2*<sup>+ΔFM2</sup>, *Otx1*<sup>-/-</sup>, *Otx2*<sup>+/-</sup>, *Otx2*<sup>ΔFM/ΔFM2</sup>, *Otx1*<sup>+/-</sup> *Otx2*<sup>+ΔFM</sup>, *Otx2*<sup>ΔFM/ΔFM</sup>, *Otx1*<sup>+/-</sup> *Otx2*<sup>ΔFM2/ΔFM2</sup> and *Otx1*<sup>-/-</sup> *Otx2*<sup>+ΔFM2</sup> mutants. *Otx1*<sup>+/-</sup> *Otx2*<sup>ΔFM2/-</sup> was affected to the same extent as *Otx2*<sup>ΔFM2/-</sup> (f); furthermore, defects in *Otx1*<sup>+/-</sup> *Otx2*<sup>ΔFM2/-</sup> were as severe as those in *Otx1*<sup>-/-</sup> *Otx2*<sup>ΔFM2/ΔFM2</sup> (h). Arrowheads indicate the position of the isthmus. Scale bars: 400 μm. (B) Marker analysis of the defects in *Otx1*<sup>-/-</sup> *Otx2*<sup>ΔFM/ΔFM</sup> at E10.5; *Otx2* (a), *Pax6* (b), *Fgf8* (c) and *Emx2* (d) expression. See Fig. 3C for the expression in wild-type embryos. Arrows in a and b indicate residual *Otx2*- and *Pax6*-positive domains, respectively. Scale bars: 400 μm.

8B) sequence is noteworthy, although its significance remains for future studies to investigate.

Based on these comparative genomic analyses, the existence of enhancer activity in domain  $\beta$  of zebrafish *Otx2* was determined. A 0.6 kb zebrafish *Otx2* region covering the 170 bp (Fig. 8B) in the middle was isolated by PCR. Using the 1.8 kb promoter, this 0.6 kb region clearly directed  $\beta$ -gal expression in mouse forebrain and midbrain (Fig. 8A, part b).

## Discussion

Kurokawa et al. (Kurokawa et al., 2004) reported the identification of enhancers of *Otx2* expression in epiblast (EP) and anterior neuroectoderm (AN). The present report identifies enhancers of *Otx2* expression in forebrain and midbrain. In contrast to the enhancers of *Otx2* expression in distal/anterior visceral endoderm (DVE/AVE), anterior mesendoderm (AME) and cephalic mesenchyme (CM) (Kimura et al., 1997; Kimura et al., 2000), all of these ectodermal enhancers were found at considerable distances from the coding region. Furthermore, at least two distinct enhancers of *Otx2* expression exist in each ectoderm at each step. Fundamental questions remain as to how essential such enhancer organization is to *Otx2* gene functions and how it was established phylogenetically.

### Enhancers of *Otx2* expression in forebrain and midbrain

The separation of the enhancer of *Otx2* expression in forebrain

and midbrain later than E8.5 from the AN enhancer was unexpected. *Otx2* expression initially covers the entire anterior neuroectoderm, but is subsequently lost in the most anterior region corresponding to the dorsal telencephalon. This change can be explained readily by the transition from *Otx2* expression under the AN enhancer to that under the FM and FM2 enhancers.  $\beta$ -gal expression under the AN enhancer is evident at E8.0, but not at E8.5. FM and FM2 enhancer activities are not found at E8.0 over the entire anterior neuroectoderm, but become apparent at E8.5.  $\beta$ -Gal expression is sensitive and stable, usually persisting longer than the expression of endogenous gene products. However, the AN enhancer must retain the activity at the stage when the *Emx2* expression takes place (three-somite stage) as demonstrated by *Otx2*<sup>ΔAN/ΔAN</sup> *Emx2*<sup>-/-</sup> mutants (Kurokawa et al., 2004). The timing of the switch from the AN enhancer to FM/FM2 enhancers corresponds to the stage critical for the regionalization of the rostral brain (see Introduction).

More unexpected was the presence of two distinct enhancers, FM and FM2, of *Otx2* expression in forebrain and midbrain. Not only are the overall sequences not conserved between FM and FM2 enhancers, there are no apparent conserved sequences between them except for TCF/LEF-binding sites. The overall sequences in the FM enhancer region are conserved in mouse, human and *Xenopus*. The FM2 enhancer, which is not conserved in human or *Xenopus*, is most probably unique to the rodent. This raises questions for future studies regarding whether human *OTX2* functions without the

second FM2 enhancer or whether the human *OTX2* gene acquired the second FM enhancer independently. Does the second FM enhancer exist in avian or *Xenopus*? Moreover, it is possible that the putative second EP/AN enhancer that failed to be identified by Kurokawa et al. (Kurokawa et al., 2004) is also unique to the rodent.


**Organization of *Otx2* enhancers**

Analysis of *Otx* homologues in lamprey suggests that the ancestral vertebrate originated with a single copy of the *Otx* gene and that divergence into the *Otx2* and *Otx1* lineages occurred in the gnathostome lineage (Ueki et al., 1998; Williams and Holland, 1998; Tomsa and Langeland, 1999;

Germot et al., 2001). In the tetrapod lineage, *Otx2* is thought to have retained its ancestral roles. By contrast, *Otx1* appears to have been co-opted for more complex functions associated with vertebrate brains (Acampora et al., 1996; Acampora et al., 1999; Suda et al., 1999; Morsli et al., 1999; Mazan et al., 2000). However, the specialization of *Otx2* and *Otx1* functions appears quite divergent in the lineage leading to the extant teleosts (Li et al., 1994; Mori et al., 1994; Mercier et al., 1995). In light of the essential roles of *Otx* in head development, the question of how the organizations of *Otx* enhancers in each vertebrate are related is one of keen interest. The mouse *Otx1* locus has no regions homologous to the mouse *Otx2* enhancers identified.

**A**

**(a)**



**B**

		<b>TCF/LEF</b>	
Mouse	1:GGGCTTGTG--CT-----GC-C-C---G--GC-TGAACAG-TGTTCAAAGG		35
Zebrafish	1:GGGTTTGTG-TTTAA-----GGGC-CGCA--G--G--T---CGGTTGTTCAAAG-		38
Fugu Otx2a	1:-----TG-G--G--A-----GGGGG-TTG-AGGGCTGCAGG-TCCGGCTGTTCAAAG-		39
Fugu Otx2b	1:-GG--TG-GAAGTAATGGGGGGGGGGCAAG-AGGGGAGC-GGTTCCGGCTGTTCAAAGG		54
	* * *		* * * * * * * * * *
		<b>TCF/LEF</b>	<b>OTX</b>
Mouse	36:C---TTCGC--TGGGCCTTGTG-----CCACTGT-GTGG-GGATTA-G-GC-CT--G-GC		77
Zebrafish	39:CAAACT--C--TGTGCATTGTG-----GGGTG--GCGGAGGATTA-GATCTCTCCAGCCC		86
Fugu Otx2a	40:C-----CACTCTGTGCATTGTGTTGGGT---AGTAG--G-GGATTA-GGTCTCTCCAG---		83
Fugu Otx2b	55:C---TGGCTTTTGTGATTGTG--GGTC--AGTTG--G-GGATTAAGGTC-CT-CTG---		98
	* * * * *	* * * * *	* * * * *
		<b>SOX</b>	
Mouse	78:GGTCT-G-AGAATTGCCC-TTCTAATTA AAAAGGATAAA-A-GATA-G---A-AG-TA--		124
Zebrafish	87:AG-C---AGAATTGCCC-TTCTAATTA AAAAGGATAAAGA-GGTAGGAAAATAG--AGG		137
Fugu Otx2a	84:-G-CTA-CAGAATTG-C TTCTAATTA AAAAGGATAAA-GATG-TAGAAAAATGGCGA-G		136
Fugu Otx2b	99:TG-C-AGCAGAA-TAGCCCTCTAATTA AAAAGGATAAA-----G---AA-GGC-A--		140
	* * * * *	* * * * *	* * * * *
		<b>PAX</b>	
Mouse	125:--GC-----A-T-TAGACT-AA-A--ACAGAGCAGTG-ATACTTCA-CAGGCTGA		164
Zebrafish	138:GGC-----ACTGTTGGGTGGA-A--A-AGA--A---A-A---AGAAGG--GG		170
Fugu Otx2a	137:GGGCAACTACTACTGT---AG-AAAAG-AC-G-G--GGGTGGA---A--A-GC--A		174
Fugu Otx2b	141:--G-AAAAATA--GT-----G-AGAGGCAC-----GGGAGG-----A--A-GC---		169
	* * * * *	* * * * *	* * * * *

**Fig. 8.** Genome organization in fish *Otx* loci. (A) Locations of the 22 domains conserved among mouse, human and *Xenopus* in pufferfish and zebrafish *Otx* loci. No homologous region existed in the *FrOtx1* locus. Domains that exhibited enhancer activity are shown by red bars. Regions homologous to the mouse FM2 enhancer region (indicated by a yellow bar) were also not found in fish genomes. White boxes indicate the coding regions. The numbers below each bar represent sequence identity with the mouse counterpart in percentage terms.  $\beta$ -Gal staining in b yields expression directed by a 600 bp region covering domain  $\beta$  in zebrafish *Otx2*. (B) Sequence alignment of domain  $\beta$  in zebrafish and two pufferfish *Otx2* loci. Red square indicates a sequence conserved throughout gnathostome *Otx2* FM regions, the significance of which is currently unknown. Scale bars: 400  $\mu$ m.

In the genomic region surrounding *Otx2*-coding region, 22 domains are conserved in mouse, human and *Xenopus*. The organization of these domains is also conserved among these animals (Kurokawa et al., 2004), and probably throughout all tetrapods. Furthermore, nine and five of these domains are conserved in *FrOtx2a* and zebrafish *Otx2*, respectively, in the same array (Fig. 8A). To consider these *Otx2*-cis elements in evolutionary terms, *Otx2* genome information is desired for coelacanth/lungfish, shark and lamprey. With the exception of the FM2 enhancer, all *Otx2* enhancers identified correspond to one of these 22 domains; enhancer activities were confirmed in six domains in mouse in the present and accompanying study (Kurokawa et al., 2004). Many other domains may also exhibit enhancer activities at later stages.

Visceral endoderm is unique to mammals; the neural crest cells responsible for generation of cephalic mesenchyme arose with vertebrate evolution. Moreover, mesendoderm is common to chordates (Satou et al., 2001). In *Xenopus Otx2* and zebrafish *Otx2*, the regions homologous to the mouse non-ectodermal enhancers (domain  $\alpha$ ) also exist near the coding region; it remains for future studies to determine whether the domains retain these non-ectodermal enhancer activities. By contrast, non-ectodermal enhancers occur at about 3' 15 kb downstream in *FrOtx2a*, and overall sequences are not conserved (Kimura et al., 1997) (C.K.-Y., I.M. and S.A., unpublished).

EP and AN enhancer regions are not conserved in either zebrafish or pufferfish (see Kurokawa et al., 2004). The lack of conservation of the AN enhancer region in these fish genomes was particularly unexpected. *Otx2* alone in tetrapod and all *Otx* genes in zebrafish are expressed in the anterior neuroectoderm. By contrast, the FM enhancer region (domain  $\beta$ ) is deeply conserved in gnathostome *Otx2*. Obviously, discussion of the phylogenetic significance of the non-conservation of the EP/AN enhancer region and the conservation of the FM region requires the identification of the second mouse EP/AN enhancer. Nevertheless, the differences in *Otx2* expression in anterior neuroectoderm in teleost and tetrapod is notable. In tetrapods, *Otx2* is initially expressed in the entire neuroectoderm (under AN enhancer) and subsequently the expression is lost in the anterior region, which corresponds to the dorsal telencephalon (under FM enhancer). In zebrafish, *Otx2* is not expressed in the most anterior part of the neuroectoderm, even at the earliest phase (Li et al., 1994; Mori et al., 1994). It is tempting to speculate that in fish the FM enhancer might function also as the AN enhancer. A comprehensive analysis of *Otx* enhancers in fish is awaited (Kimura et al., 1997; Kimura-Yoshida et al., 2004).

### **Otx2 functions in forebrain/midbrain and upstream regulators**

After an analysis of *Otx1<sup>+/-</sup>Otx2<sup>+/-</sup>* double mutants, we reported previously that *Otx2* cooperates with *Otx1* for midbrain development (Suda et al., 1997). The cooperation, however, could not be examined in *Otx1<sup>-/-</sup>Otx2<sup>+/-</sup>*, *Otx1<sup>+/-</sup>Otx2<sup>-/-</sup>* or *Otx1<sup>-/-</sup>Otx2<sup>-/-</sup>* mutants because of earlier visceral endoderm defects in *Otx2<sup>-/-</sup>* mutants and postnatal lethality of *Otx1<sup>+/-</sup>Otx2<sup>+/-</sup>* mutants. This situation obscured the onset and the extent of the cooperation between *Otx1* and *Otx2* in rostral brain development (Acampora et al., 1997; Suda et al., 1997). With the AN and FM/FM2 enhancers and their mutants, we now propose that the initial brain regionalization

occurs around the three-somite stage under the AN enhancer, at a stage when FM and FM2 enhancers are still inactive (see Kurokawa et al., 2004). Metencephalic, mesencephalic, diencephalic and telencephalic regions differentiate at this stage; however, these regions are not yet determined when *Otx2* expression under FM and FM2 enhancers takes place. In the most severe *Otx1<sup>-/-</sup>Otx2<sup>ΔFM/ΔFM</sup>* mutants, which lacked most of mesencephalon and diencephalon at E10.5, their primordia or the *Otx2*-, *Emx2*- and *Pax2*-positive regions developed normally at the 5 somite stage.

Even in the most severe *Otx1<sup>-/-</sup>Otx2<sup>ΔFM/ΔFM</sup>* mutants *Emx2*-positive telencephalon developed normally. Apparently, the cooperation between *Otx1* and *Otx2* under FM and FM2 enhancers does not participate in telencephalon development. This is consistent with the lack of *Otx2* expression under these enhancers in dorsal telencephalon and of *Otx1* expression in ventral telencephalon (Frantz et al., 1994). Moreover, an analysis of the mutants suggests that the future telencephalic region has already differentiated when *Otx1* cooperates with *Otx2* under FM and FM2 enhancers. However, the precise anterior limit of the regions affected by the loss of the cooperation remains to be determined.

In *Otx2<sup>ΔFM/-</sup>* and *Otx2<sup>ΔFM2/-</sup>* mutants, *Fgf8*-positive isthmus expanded at E10.5 and cerebellum was enlarged at E15.5 as in *Otx1<sup>+/-</sup>Otx2<sup>+/-</sup>* mutants (Suda et al., 1997). In a series of double mutants in Fig. 7A, the lower the *Otx* dose and the more severe the phenotype, the more expanded was the *Fgf8*-positive isthmus. Most probably, mesencephalic and diencephalic regions that initially differentiated at the three-somite stage were secondarily transformed into metencephalon in these mutants (Acampora et al., 1997; Suda et al., 1997). Interestingly, however, *Fgf8*-positive isthmus was lost in the most severe *Otx1<sup>-/-</sup>Otx2<sup>ΔFM/ΔFM</sup>* mutant (Fig. 7B, part c). It has been reported that the induction of the *Fgf8* expression in isthmus is independent of *Otx2*; rather, that *Otx2*, along with *Gbx2*, refines the *Fgf8* expression (Li and Joyner, 2001; Martinez-Barbera et al., 2001; Ye et al., 2001). However, these are observations made in the presence of *Otx1* expression. Moreover, *Fgf8* expression is also lost in the anterior neural ridge of *Otx1<sup>-/-</sup>Otx2<sup>ΔFM/ΔFM</sup>* mutant. The details of the double mutant defects warrant examination in future studies.

The double mutants in Fig. 7A also indicate that OTX dose dependence differs regionally, i.e. the posterior mesencephalon requires elevated OTX for development. The onset of FM and FM2 enhancer activities, at around E8.5, coincides with the stage when broad, faint *Fgf8* expression contracts and the boundary between the midbrain and the hindbrain or the isthmus is established. A higher OTX dose might be required in the more posterior portion of the forebrain/midbrain to suppress posteriorizing signals from isthmus and/or anterior hindbrain (Martinez et al., 1999). The caudal end of the activities of both FM and FM2 enhancers coincides with the midbrain/hindbrain boundary. An attempt to identify the sequences that delineate the expression at the boundary is currently under way.

The identification of direct upstream regulators of *Otx2* expression at each site and at each stage is also an objective of our enhancer analysis. Potential TCF/LEF binding sites are essential in both FM and FM2 enhancers, whereas a putative OTX-binding site is additionally required in the FM enhancer. These sites in the FM enhancer are conserved in mouse,

human, *Xenopus*, pufferfish and zebrafish; one TCF/LEF-binding site is converted into a potential SOX-binding site in the fish. It is probable that *Otx2* expression under the FM enhancer is initiated by OTX2 directed by the AN enhancer. Subsequently *Otx2* expression under the FM and FM2 enhancers may be regulated by the WNT and TCF cascade. *Wnt* and *Tcf/Lef* expressions appear in dorsal forebrain/midbrain following E8.5 and in the cortical hem following E10 (Parr et al., 1993; Galceran et al., 2000; Lee et al., 2000).

This investigation, however, presents only a starting point in terms of the elucidation of many unknown factors that directly regulate these enhancers. AN enhancer analysis by Kurokawa et al. (Kurokawa et al., 2004) has been most successful in narrowing the focus of the essential, sufficient region; however, this essential region is still 90 bp long. The limited size of mouse anterior neuroectoderm also limits the biochemical identification of factors that bind to the 90 bp sequence. Full FM activity is harbored in the *Apal/HindIII* 1.4 kb fragment; a 364 bp region within this fragment was essential to the activity and could not be shortened further. The FM region is also present in zebrafish *Otx2*, *FrOtx2a* and *FrOtx2b*, where the TCTAATTA AAAWGGATA sequence is conserved, the significance of which remains for future studies. The *BsmI/BamHI* 1.0 kb region displayed full FM2 enhancer activity. Within this region, *BsmI/HincII*127bp was essential for FM2 activity; however, the 127 bp fragment alone did not exhibit this activity, and neither did the 3.0 kb FM2 region in the human *OTX2* locus. Moreover, the EP enhancer required multiple domains exceeding 2.3 kb. Enhancers that regulate expression in vivo during development may commonly exhibit such complexity, meaning that novel strategies will be required to identify critical upstream regulators with such enhancers.

We thank Ms S. Nagayoshi, T. Ohmura and Mr N. Takeda for their technical assistance. We are indebted to Drs N. Heintz, P. Gruss and G. R. Martin, who generously provided a number of plasmids; and to Dr H. Hamada, who kindly provided us *Lefty-Cre* mice. We are also grateful to the Laboratory for Animal Resource and Genetic Engineering for the housing of mice. This work was supported by a Grant-in-Aid for Scientific Research on Priority Areas from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

## References

- Acampora, D., Mazan, S., Avantaggiato, V., Barone, P., Tuorto, F., Lallemand, Y., Brulet, P. and Simeone, A. (1996). Epilepsy and brain abnormalities in mice lacking the *Otx1* gene. *Nat. Genet.* **14**, 218-222.
- Acampora, D., Avantaggiato, V., Tuorto, F. and Simeone, A. (1997). Genetic control of brain morphogenesis through *Otx* gene dosage requirement. *Development* **124**, 3639-3650.
- Acampora, D., Avantaggiato, V., Tuorto, F., Barone, P., Perera, M., Choo, D., Wu, D., Corte, G. and Simeone, A. (1999). Differential transcriptional control as the major molecular event in generating *Otx1*<sup>-/-</sup> and *Otx2*<sup>-/-</sup> divergent phenotypes. *Development* **126**, 1417-1426.
- Ang, S.-L., Conlon, R. A., Jin, O. and Rossant, J. (1994). Positive and negative signals from mesoderm regulate the expression of mouse *Otx2* in ectoderm explants. *Development* **120**, 2979-2989.
- Araki, I. and Nakamura, H. (1999). Engrailed defines the position of dorsal di-mesencephalic boundary by repressing diencephalic fate. *Development* **126**, 5127-5135.
- Bosse, A., Zulch, A., Becker, M. B., Torres, M., Gomez-Skarmeta, J. L., Modolell, J. and Gruss, P. (1997). Identification of the vertebrate Iroquois homeobox gene family with overlapping expression during early development of the nervous system. *Mech. Dev.* **69**, 169-181.
- Bouillet, P., Chazaud, C., Oulad-Abdelghani, M., Dolle, P. and Chambon, P. (1995). Sequence and expression pattern of the *Stra7* (*Gbx-2*) homeobox-containing gene induced by retinoic acid in P19 embryonic carcinoma cells. *Dev. Dyn.* **204**, 372-382.
- Brannon, M., Gomperts, M., Sumoy, L., Moon, R. T. and Kimelman, D. (1997). A  $\beta$ -catenin/XTcf-3 complex binds to the siamois promoter to regulate dorsal axis specification in *Xenopus*. *Genes Dev.* **11**, 2359-2370.
- Broccoli, V., Boncinelli, E. and Wurst, W. (1999). The caudal limit of *Otx2* expression positions the isthmic organizer. *Nature* **401**, 164-168.
- Crossley, P. H. and Martin, G. R. (1995). The mouse *Fgf8* gene encodes a family of polypeptides and is expressed in regions that direct outgrowth and patterning in the developing embryo. *Development* **121**, 439-451.
- Crossley, P. H., Martinez, S. and Martin, G. R. (1996). Midbrain development induced by FGF8 in the chick embryo. *Nature* **380**, 66-68.
- Czerny, T. and Busslinger, M. (1995). DNA-binding and transcription properties of Pax-6. Three amino acids in the paired domain are responsible for the different sequence recognition of Pax-6 and BSAP (Pax-5). *Mol. Cell. Biol.* **15**, 2858-2871.
- Flint, J., Tufarelli, C., Peden, J., Clark, K., Daniels, R. J., Hardison, R., Miller, W., Philipsen, S., Tan-Un, K. C., McMorro, et al. (2001). Comparative genome analysis delimits a chromosomal domain and identifies key regulatory elements in the  $\alpha$  globin cluster. *Hum. Mol. Genet.* **10**, 371-382.
- Frantz, G. D., Weimann, J. M., Levin, M. E. and McConnell, S. K. (1994). *Otx1* and *Otx2* define layers and regions in developing cerebral cortex and cerebellum. *J. Neurosci.* **14**, 5725-5740.
- Galceran, J., Miyashita-Lin, E. M., Devaney, E., Rubenstein, J. L. R. and Grosschedl, R. (2000). Hippocampus development and generation of dentate gyrus granule cells is regulated by LEF1. *Development* **127**, 469-482.
- Germot, A., Lecointre, G., Plouhinec, J.-L., le Mentec, C., Girardot, F. and Mazan, S. (2001). Structural evolution of *Otx* genes in craniates. *Mol. Biol. Evol.* **18**, 1668-1678.
- Inoue, T., Nakamura, S. and Osumi, N. (2000). Fate mapping of the mouse prosencephalic neural plate. *Dev. Biol.* **219**, 373-383.
- Kimura, C., Takeda, N., Suzuki, M., Oshimura, M., Aizawa, S. and Matsuo, I. (1997). Cis-acting elements conserved between mouse and pufferfish *Otx2* genes govern the expression in mesencephalic neural crest cells. *Development* **124**, 3929-3941.
- Kimura, C., Yoshinaga, K., Tian, E., Suzuki, M., Aizawa, S. and Matsuo, I. (2000). Visceral endoderm mediates forebrain development by suppression posteriorizing signals. *Dev. Biol.* **225**, 304-321.
- Kimura-Yoshida, C., Kitajima, K., Oda-Ishii, I., Tian, E., Suzuki, M., Yamamoto, M., Suzuki, T., Kobayashi, M., Aizawa, S. and Matsuo, I. (2004). Characterization of the pufferfish *Otx2* cis-regulators reveals evolutionarily conserved genetic mechanisms for the vertebrate head specification. *Development* **131**, 57-71.
- Kobayashi, D., Kobayashi, M., Matsumoto, K., Ogura, T., Nakafuku, M. and Shimamura, K. (2002). Early subdivisions in the neural plate define distinct competence for inductive signals. *Development* **129**, 83-93.
- Kurokawa, D., Takasaki, N., Kiyonari, H., Nakayama, R., Kimura-Yoshida, C., Matsuo, I. and Aizawa, S. (2004). Regulation of *Otx2* expression and its functions in mouse epiblasts and anterior neuroectoderm. *Development* **131**, 3307-3317.
- Lee, S. M. K., Tole, S., Grove, E. and McMahon, A. P. (2000). A local *Wnt-3a* signal is required for development of the mammalian hippocampus. *Development* **127**, 457-467.
- Li, J. Y. H. and Joyner, A. L. (2001). *Otx2* and *Gbx2* are required for refinement and not induction of mid-hindbrain gene expression. *Development* **128**, 4979-4991.
- Li, Y., Allende, M. L., Finkelstein, R. and Weinberg, E. S. (1994). Expression of two zebrafish orthodenticle-related genes in the embryonic brain. *Mech. Dev.* **48**, 229-244.
- Mao, C.-A., Gan, L. and Klein, W. H. (1994). Multiple *Otx* binding site required for expression of the *Strongylocentrotus purpuratus* *Spec2a* gene. *Dev. Biol.* **165**, 229-242.
- Martinez, S., Crossley, P. H., Cobos, I., Rubenstein, J. L. R. and Martin, G. R. (1999). FGF8 induces formation of an ectopic isthmic organizer and isthmocerebellar development via a repressive effect on *Otx2* expression. *Development* **126**, 1189-1200.
- Martinez-Barbera, J. P., Signore, M., Boyl, P. P., Puelles, E., Acampora, D., Gogoi, R., Schubert, F., Lumsden, A. and Simeone, A. (2001). Regionalisation of anterior neuroectoderm and its competence in responding

- to forebrain and midbrain inducing activities depend on mutual antagonism between OTX2 and GBX2. *Development* **128**, 4789-4800.
- Matsunaga, E., Araki, I. and Nakamura, H.** (2000). Pax6 defines the dimesencephalic boundary by repressing En1 and Pax2. *Development* **127**, 2357-2365.
- Matsuo, I., Kuratani, S., Kimura, C., Takeda, N. and Aizawa, S.** (1995). Mouse Otx2 functions in the formation and patterning of rostral head. *Genes Dev.* **9**, 2646-2658.
- Mazan, S., Jaillard, D., Baratte, B. and Janvier, P.** (2000). Otx1 gene-controlled morphogenesis of the horizontal semicircular canal and the origin of the gnathostome characteristics. *Evol. Dev.* **2**, 186-193.
- Mercier, P., Simeone, A., Cotelli, F. and Boncinelli, E.** (1995). Expression pattern of two otx genes suggests a role in specifying anterior body structures in zebrafish. *Int. J. Dev. Biol.* **39**, 559-573.
- Mertin, S., McDowall, S. G. and Harley, V. R.** (1999). The DNA-binding specificity of SOX9 and other SOX proteins. *Nucleic Acids Res.* **27**, 1359-1364.
- Millet, S., Campbell, K., Epstein, D. J., Losos, K., Harris, E. and Joyner, A. L.** (1999). A role for Gbx2 in repression of Otx2 and positioning the mid-hindbrain organizer. *Nature* **401**, 161-164.
- Mori, H., Miyazaki, Y., Morita, T., Nitta, H. and Mishina, M.** (1994). Different spatio-temporal expression of three otx homeoprotein transcripts during zebrafish embryogenesis. *Mol. Brain Res.* **27**, 221-231.
- Morsli, H., Tuorto, F., Choo, D., Postiglione, M. P., Simeone, A. and Wu, D. K.** (1999). Otx1 and Otx2 activities are required for the normal development of the inner ear. *Development* **126**, 2335-2343.
- Müller, F., Blader, P. and Strähle, U.** (2002). Search for enhancers, teleost models in comparative genomic and transgenic analysis of cis regulatory elements. *BioEssays* **24**, 564-572.
- Oliver, G., Mailhos, A., Wehr, R., Copeland, N. G., Jenkins, N. A. and Gruss, P.** (1995). Six3, a murine homologue of the sine oculis gene, demarcates the most anterior border of the developing neural plate and is expressed during eye development. *Development* **121**, 4045-4055.
- Parr, B. A., Shea, M. J., Vassileva, G. and McMahon, A. P.** (1993). Mouse wnt genes exhibit discrete domains of expression in the early embryonic CNS and limb buds. *Development* **119**, 247-261.
- Rhinn, M., Dierich, A., Shawlot, W., Behringer, R. R., le Meur, M. and Ang, S.-L.** (1998). Sequential roles for Otx2 in visceral endoderm and neuroectoderm for forebrain and midbrain induction and specification. *Development* **125**, 845-856.
- Rowitch, D. H. and McMahon, A. P.** (1995). Pax-2 expression in the murine neural plate precedes and encompasses the expression domains of Wnt-1 and En-1. *Mech. Dev.* **52**, 3-8.
- Satou, Y., Imai, K. S. and Satoh, N.** (2001). Early embryonic expression of a LIM-homeobox gene Cs-lhx3 is downstream of  $\beta$ -catenin and responsible for the endoderm differentiation in *Ciona savignyi* embryos. *Development* **128**, 3559-3570.
- Schwarz, M., Alvarez-Bolado, G., Dressler, G., Urbanek, P., Busslinger, M. and Gruss, P.** (1999). Pax2/5 and Pax6 subdivide the early neural tube into three domains. *Mech. Dev.* **82**, 29-39.
- Shimamura, K. and Rubenstein, J. L.** (1997). Inductive interactions direct early regionalization of the mouse forebrain. *Development* **124**, 2709-2718.
- Simeone, A., Acampora, D., Gulisano, M., Stornaiuolo, A. and Boncinelli, E.** (1992). Nested expression domains of four homeobox genes in the developing rostral brain. *Nature* **358**, 687-690.
- Simeone, A., Acampora, D., Mallamaci, A., Stornaiuolo, A., D'Apice, M. R., Nigro, V. and Boncinelli, E.** (1993). A vertebrate gene related to orthodenticle contains a homeodomain of the bicoid class and demarcates anterior neuroectoderm in the gastrulating mouse embryo. *EMBO J.* **12**, 2735-2747.
- Suda, Y., Matsuo, I., Kuratani, S. and Aizawa, S.** (1996). Otx1 function overlap with Otx2 in development of mouse forebrain and midbrain. *Genes Cells* **1**, 1031-1044.
- Suda, Y., Matsuo, I. and Aizawa, S.** (1997). Cooperative between Otx1 and Otx2 genes in developmental patterning of rostral brain. *Mech. Dev.* **69**, 125-141.
- Suda, Y., Nakabayashi, J., Matsuo, I. and Aizawa, S.** (1999). Functional equivalency between Otx2 and Otx1 in development of the rostral head. *Development* **126**, 743-757.
- Suda, Y., Hossain, Z. M., Kobayashi, C., Hatano, O., Yoshida, M., Matsuo, I. and Aizawa, S.** (2001). Emx2 directs the development of diencephalon in cooperation with Otx2. *Development* **128**, 2433-2450.
- Tian, E., Kimura, C., Takeda, N., Aizawa, S. and Matsuo, I.** (2002). Otx2 is required to respond to signals from anterior neural ridge for forebrain specification. *Dev. Biol.* **242**, 204-223.
- Thomas, P. and Beddington, R.** (1996). Anterior primitive endoderm may be responsible for patterning the anterior neural plate in the mouse embryo. *Curr. Biol.* **6**, 1487-1496.
- Tomsa, J. M. and Langeland, J. A.** (1999). Otx expression during lamprey embryogenesis provides insights into the evolution of the vertebrate head and jaw. *Dev. Biol.* **207**, 26-37.
- Ueki, T., Kuratani, S., Hirano, S. and Aizawa, S.** (1998). Otx cognates in a lamprey, *Lampetra japonica*. *Dev. Genes Evol.* **208**, 223-228.
- Walther, C. and Gruss, P.** (1991). Pax-6, a murine paired box gene, is expressed in the developing CNS. *Development* **113**, 1435-1449.
- Wassarman, K. M., Lewandoski, M., Campbell, K., Joyner, A. L., Rubenstein, J. L. R., Martinez, S. and Martin, G. R.** (1997). Specification of the anterior hindbrain and establishment of a normal mid/hindbrain organizer is dependent on Gbx2 gene function. *Development* **124**, 2923-2934.
- Williams, N. A. and Holland, P. W. H.** (1998). Gene and domain duplication in the chordate Otx gene family. Insights from amphioxus Otx. *Mol. Biol. Evol.* **15**, 600-607.
- Yamamoto, M., Meno, C., Sakai, Y., Shiratori, H., Mochida, K., Ikawa, Y., Saijoh, Y. and Hamada, H.** (2001). The transcription factor FoxH1 (FAST) mediates Nodal signaling during anterior-posterior patterning and node formation in the mouse. *Genes Dev.* **15**, 1242-1256.
- Yang, X. W., Model, P. and Heintz, N.** (1997). Homologous recombination based modification in *Escherichia coli* and germline transmission in transgenic mice of a bacterial artificial chromosome. *Nat. Biotech.* **15**, 859-865.
- Ye, W., Bouchard, M., Stone, D., Liu, X., Vella, F., Lee, J., Nakamura, H., Ang, S.-L., Busslinger, M. and Rosenthal, A.** (2001). Distinct regulators control the expression of the mid-hindbrain organoizer signal FGF8. *Nat. Neurosci.* **4**, 1175-1181.
- Yoshida, M., Suda, Y., Matsuo, I., Miyamoto, N., Takeda, N., Kuratani, S. and Aizawa, S.** (1997). Emx1 and Emx2 functions in development of dorsal telencephalon. *Development* **124**, 101-111.